Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

BP1 is a key player in DNA repair and together with BRCA1 regulate selection of DNA double strand break repair mechanisms. Localization of DNA repair factors to sites of DNA damage by 53BP1 is ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Bicara Therapeutics Inc.’s BCAX share price has dipped by 6.53%, which has investors questioning if this is right time to buy ...

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and ...